UNSPSC 51292801: Milnacipran

This classification denotes an antidepressant agent and adrenergic agent with the molecular formula C15H22N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G56VK1HF36, chemically known as cyclopropanecarboxamide, 2-(aminomethyl)-n,n-diethyl-1-phenyl-, cis-(+-)- but generally known as milnacipran, which bears US NIH Compound Identifier 65833. European Medicines Agency schedules Milnacipran in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08965MIG.

UNSPSC 51292801 Milnacipran is a Commodity code that encompasses individual pharmaceutical products, though recent state and local solicitations under this code show activity focused on broader pharmaceutical procurement — including naloxone (an opioid antagonist), generic multi-source pharmaceuticals, and over-the-counter products — rather than milnacipran specifically. State and local governments use this code tier to procure specific drug products for health departments, community health initiatives, and pharmacy benefit programs serving employees and retirees. Issuing bodies include county health departments, state health and human services commissions, and cooperative purchasing alliances spanning multiple states and jurisdictions. The Seminole County, Florida procurement exemplifies direct county-level purchasing for community health support, while the Texas HHS Commission and Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent state-level and multi-jurisdictional approaches to pharmaceutical sourcing through established wholesaler networks.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, signaling future formal procurement. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, including Oregon, with proposals due March 26, 2026, and awards effective July 1, 2026; vendors must maintain relationships with authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and agree to a 3 percent administrative fee on all contract purchases.